AutismNCT02090491
MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation
An observational study of Autism, run by Northeastern University at 1 site in United States.
Trial summary
Autism Spectrum Disorder (ASD) is a collection of complex neurodevelopmental disorders characterized by qualitative impairments in socialization, communication, and circumscribed interests, including stereotypical behavior patterns and behavioral rigidity to changes in routines (American Psychiatric Association… Read more about this study
- Who is it for?
- Ages 5 to 20 years
- Conditions the study is for
- Autism
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2013to Oct 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 20 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Group 1: Six (6) students from the Discovery School and their respective support staff. Inclusion criteria include a diagnosis of ASD and enrollment in the Discovery School due to frequently observed challenging behaviors. Reporters will include: 2 teachers, HCP and parent/guardian. Group 2: Fourteen (14) students receiving services from Center for Discovery (but outside the Discovery School), their respective support staff, and, for those who live at home, their parents. Inclusion criteria includes a diagnosis of ASD, seven (7) students who reside in a CfD provided campus home, and seven (7) students who reside in the local community with their parents. Reporters will include: 2 teachers, HCP, residential staff and parents. Stakeholders: Healthcare professionals, classroom teachers, residential staff, and parents who support students with ASD in Groups 1 and 2 above.
Who may be able to join
- Student Participants:
- Meet standard classroom selection criteria of age, gender, intellectual ability, communication ability and behavioral characteristics (frequency and duration of maladaptive behaviors).
- Be enrolled at Center for Discovery, have a Behavioral Intervention Plan (BIP), and an Individualized Education Plan (IEP).
- Have a diagnosis of autism.
- Be between the ages of 5 and 21 years, inclusive.
- Tolerate wearing physiological wrist, ankle, and chest monitors.
Show all 15Show fewer
- Residential and School Staff:
- Employed at The Center for Discovery.
- Meet Center for Discovery requirements for working with students in the classroom or residence and have experience in teaching or intervening with students who exhibit maladaptive behaviors.
- Willing to consent to add data to the system via the supplied tablet for the duration of the study.
- Willing to consent to participate in either focus groups or individual interviews about their experience of using the system and to be video recorded doing so.
- Parent Participants:
- Be the parent or legal guardian of one of the 20 students enrolled in the study.
- Willing to consent to add data to the system via the supplied tablet for the duration of the study.
- Willing to consent to participate in either focus groups or individual interviews about their experience using the system and to be video recorded doing so.
Who cannot join
- Student Participants:
- Younger than 5 years at the start of the school year.
- Not reach the age of 21 years prior to the end of the school year during which the study will take place.
- Not enrolled at Center for Discovery.
- Do not tolerate wearing physiological monitors after repeated trials of modeling, desensitization, shaping, and reinforcement.
- Residential and School Staff:
Show all 13Show fewer
- Have not been employed for at least one year prior to participating in the study.
- Do not consent to adding data.
- Do not consent to participant in focus groups or interviews.
- Do not consent to being recorded during focus groups or interviews.
- Parent Participants:
- Are not the parent or legal guardian of one of the student enrolled.
- Do not consent to participate in either focus groups of individual interviews about their experience using the system and to be video recorded doing so.
Trial locations and contacts
1 site in 1 country.
About this study
Autism Spectrum Disorder (ASD) is a collection of complex neurodevelopmental disorders characterized by qualitative impairments in socialization, communication, and circumscribed interests, including stereotypical behavior patterns and behavioral rigidity to changes in routines (American Psychiatric Association, 1994). ASD is the fastest growing pervasive developmental disorder of childhood, currently estimated to affect 1 in 88 school age children (Baio, 2012). ASD typically manifests in infancy and persist throughout the lifespan. There is no known cause or cure for ASD, yet structured behavioral interventions and medications can enhance developmental outcomes. ASD has a profound impact on families and often result in enormous emotional and financial costs. Recent estimates suggest that societal costs in the US to care for all individuals diagnosed each year over their lifetime approaches $35 billion (Ganz, 2007).
Janssen Research \& Development is building a comprehensive digital platform (MENTIS) to optimize and enhance development of novel medicines and track outcomes in individuals with ASD. The MENTIS platform contains several core components, including: (1) An electronic personal healthcare record, designed specifically for individuals with ASD and their caregivers (parents, teachers, healthcare providers); (2) Integrated physiological and physical activity biosensors designed to objectively assess outcomes important in ASD, and; (3) A de-identified research data warehouse with analytic tools to better measure outcomes, assist with sub-population identification, and identify algorithms for diagnosis and treatment response detection.
The MENTIS platform is currently being designed, developed, and prepared for testing. During this process it is highly desirable to conduct feasibility and usability research with a sample of the target population to identify important system components and features, optimize design, and reduce redundancy in software development and research time. The rapid pilot study described herein is proposed to gather incipient feedback on select MENTIS system components and features from stakeholders who support individuals with ASD in a clinical setting. This pilot research will help evaluate both how well current MENTIS system features work in an applied setting and inform future directions for MENTIS platform development.
- Conditions
- Autism
- Keywords
- autism
- Medical subject headings
- Autistic Disorder
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-Report
Summary of data from all data collection cycles (includes Stakeholder entered data, biosensor data and passive system usage data) in aggregate and raw, de-identified dataset with both qualitative and quantitative information:
- Qualitative and quantitative data from Exit Interviews
- System usage data;
- Pre-post summary,
- case examples,
- de-identified video examples,
- testimonials,
- overall results.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2014 (estimated)
- Study startNov 2013
- Primary completionOct 2014
- Study completionOct 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AutismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northeastern University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Matthew S Goodwin, PhD, Principal investigator, Northeastern University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02090491
- Sponsor's protocol ID
- Janssen Research & Development
- Status last verified
- Apr 2017
- First submitted
- 1 Nov 2013
- Last updated
- 7 Apr 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation
- ClinicalTrials.gov ID
- NCT02090491
- Acronym / sponsor ID
- Janssen Research & Development
- Conditions
- Autism
- Keywords
- autism
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Northeastern UniversityUniversity, hospital or other
- Study start
- Nov 2013
- Primary completion
- Oct 2014 (actual)
- Study completion
- Oct 2014 (actual)
- First posted
- 18 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Autism Spectrum Disorder (ASD) is a collection of complex neurodevelopmental disorders characterized by qualitative impairments in socialization, communication, and circumscribed interests, including stereotypical behavior patterns and behavioral rigidity to changes in routines (American Psychiatric Association, 1994). ASD is the fastest growing pervasive developmental disorder of childhood, currently estimated to affect 1 in 88 school age children (Baio, 2012). ASD typically manifests in infancy and persist throughout the lifespan. There is no known cause or cure for ASD, yet structured behavioral interventions and medications can enhance developmental outcomes. ASD has a profound impact on families and often result in enormous emotional and financial costs. Recent estimates suggest that societal costs in the US to care for all individuals diagnosed each year over their lifetime approaches $35 billion (Ganz, 2007).
Janssen Research \& Development is building a comprehensive digital platform (MENTIS) to optimize and enhance development of novel medicines and track outcomes in individuals with ASD. The MENTIS platform contains several core components, including: (1) An electronic personal healthcare record, designed specifically for individuals with ASD and their caregivers (parents, teachers, healthcare providers); (2) Integrated physiological and physical activity biosensors designed to objectively assess outcomes important in ASD, and; (3) A de-identified research data warehouse with analytic tools to better measure outcomes, assist with sub-population identification, and identify algorithms for diagnosis and treatment response detection.
The MENTIS platform is currently being designed, developed, and prepared for testing. During this process it is highly desirable to conduct feasibility and usability research with a sample of the target population to identify important system components and features, optimize design, and reduce redundancy in software development and research time. The rapid pilot study described herein is proposed to gather incipient feedback on select MENTIS system components and features from stakeholders who support individuals with ASD in a clinical setting. This pilot research will help evaluate both how well current MENTIS system features work in an applied setting and inform future directions for MENTIS platform development.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
Who may qualify
- Ages
- 5 to 20 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Group 1: Six (6) students from the Discovery School and their respective support staff. Inclusion criteria include a diagnosis of ASD and enrollment in the Discovery School due to frequently observed challenging behaviors. Reporters will include: 2 teachers, HCP and parent/guardian. Group 2: Fourteen (14) students receiving services from Center for Discovery (but outside the Discovery School), their respective support staff, and, for those who live at home, their parents. Inclusion criteria includes a diagnosis of ASD, seven (7) students who reside in a CfD provided campus home, and seven (7) students who reside in the local community with their parents. Reporters will include: 2 teachers, HCP, residential staff and parents. Stakeholders: Healthcare professionals, classroom teachers, residential staff, and parents who support students with ASD in Groups 1 and 2 above.
Key inclusion criteria (15 listed)
- Meet standard classroom selection criteria of age, gender, intellectual ability, communication ability and behavioral characteristics (frequency and duration of maladaptive behaviors).
- Be enrolled at Center for Discovery, have a Behavioral Intervention Plan (BIP), and an Individualized Education Plan (IEP).
- Have a diagnosis of autism.
- Be between the ages of 5 and 21 years, inclusive.
- Tolerate wearing physiological wrist, ankle, and chest monitors.
Key exclusion criteria (13 listed)
- Younger than 5 years at the start of the school year.
- Not reach the age of 21 years prior to the end of the school year during which the study will take place.
- Not enrolled at Center for Discovery.
- Do not tolerate wearing physiological monitors after repeated trials of modeling, desensitization, shaping, and reinforcement.
- Have not been employed for at least one year prior to participating in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Self-Report
Time frame: 6 months
Summary of data from all data collection cycles (includes Stakeholder entered data, biosensor data and passive system usage data) in aggregate and raw, de-identified dataset with both qualitative and quantitative information: * Qualitative and quantitative data from Exit Interviews * System usage data; * Pre-post summary, * case examples, * de-identified video examples, * testimonials, * overall results.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2017.
Related trials for Autism
Recruiting
Effectiveness of Clown Therapy in Facilitating Dental Visits for Children With Autism Spectrum Disorder
Autism Spectrum Disorder (ASD
RecruitingObservational study
Sensory Profile of People With High Intellectual Potential (HIP)
High Intellectual Potential
Recruiting
Cerebellar Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder: Raynor Cerebellum Project
Autism Spectrum Disorder
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Not yet recruiting
Transdiagnostic Sleep and Circadian Treatment for Autistic Adolescents
Sleep, Autism Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matthew S Goodwin, PhD principal investigator
Northeastern University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Autism, run by Northeastern University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self-Report (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2017.